EDITORIAL
Published on 04 May 2022
Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
doi 10.3389/fonc.2022.898576
- 893 views
- Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- Research Topics
- Immune-Related Adverse Events for Patients with Lung Cancer
Immune-Related Adverse Events for Patients with Lung Cancer
31k
Total downloads
95k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
MINI REVIEW
Published on 30 Sep 2021
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
doi 10.3389/fonc.2021.720759
- 2,531 views
- 5 citations
SYSTEMATIC REVIEW
Published on 15 Sep 2021
Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
doi 10.3389/fonc.2021.708195
- 2,996 views
- 28 citations
CASE REPORT
Published on 02 Sep 2021
Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
doi 10.3389/fonc.2021.664809
- 2,657 views
- 12 citations
REVIEW
Published on 24 Aug 2021
Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
doi 10.3389/fimmu.2021.701951
- 5,938 views
- 39 citations
CASE REPORT
Published on 17 Jun 2021
Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report
doi 10.3389/fonc.2021.670415
- 1,575 views
- 1 citation
REVIEW
Published on 31 May 2021
Toxicities of Immunotherapy for Small Cell Lung Cancer
doi 10.3389/fonc.2021.603658
- 6,360 views
- 8 citations
REVIEW
Published on 28 May 2021
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
doi 10.3389/fimmu.2021.663986
- 17,831 views
- 69 citations
REVIEW
Published on 21 May 2021
Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
doi 10.3389/fonc.2021.628243
- 2,239 views
- 1 citation
CASE REPORT
Published on 10 May 2021
Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
doi 10.3389/fimmu.2021.619147
- 3,313 views
- 26 citations
SYSTEMATIC REVIEW
Published on 30 Mar 2021
Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
doi 10.3389/fimmu.2021.627197
- 3,759 views
- 19 citations
REVIEW
Published on 18 Mar 2021
Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
doi 10.3389/fonc.2021.604227
- 2,938 views
- 13 citations
Published in
Frontiers in Oncology
- Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Immunology
- 5.7 impact factor
- 9.8 citescore
Impact
- 95kTopic views
- 63kArticle views
- 31kArticle downloads